Vahh Chemicals H1 Profit Soars to Rs 3.37 Crore

Consolidated Profit After Tax reached Rs 3.37 crore for H1 FY27, up from Rs 1.87 crore in H1 FY25.
Consolidated Revenue grew to Rs 25.86 crore, compared to Rs 16.52 crore in the same period last year.

Reader Takeaway: Strong revenue growth fuels profit, while new nutraceutical subsidiary and pending Surat facility expansion drive future outlook.

What just happened

Vahh Chemicals has released its H1 FY27 financial results, showing significant growth across both standalone and consolidated metrics. On a consolidated basis, the company recorded a revenue of Rs 25.86 crore, a sharp increase from Rs 16.52 crore reported in H1 FY25. Along with the financial update, the company announced the incorporation of a new wholly-owned subsidiary, Vedant Nutrition Limited, which will focus on nutraceuticals, dietary foods, and supplements.

Why this matters

The pivot toward the nutraceutical industry through a dedicated subsidiary indicates a strategic move to diversify revenue streams beyond core chemicals. Investors will be watching how this new vertical scales. Furthermore, the company reported that Rs 2.56 crore of its IPO proceeds remain unutilized. This capital is earmarked for key projects, including a new manufacturing facility in Surat and partial debt repayment, which are essential for the company’s capital expenditure cycle.

Governance Update

The company also confirmed a change in leadership oversight, with Ms. Shubhangi Rajesh Gadia appointed as the Company Secretary and Compliance Officer, effective November 1, 2026.

What to track next

The market will focus on the execution timeline for the Surat manufacturing facility, as the full allocation of Rs 1.93 crore remains untouched. Additionally, the operational ramp-up of Vedant Nutrition Limited will be a critical indicator of the company’s ability to successfully enter the consumer-facing health product market.